Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 197-213
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.197
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.197
Table 2 A summary of the data extracted from the 135 articles included in the systematic review
No. | Gene symbol | Role in tumors | Cellular localizatioa | Target(s) | Functions and pathways | Inhibitor(s) | Ref. |
1 | USP1 | Oncogene | Nucleus | Cyclin A/D/E, Bcl2, MCL1, FANCD1, ID1 | Cell cycle, DNA Repair, apoptosis | ML323 | Xu et al[24] |
2 | USP2 | Oncogene | Cytoplasm, cytoplasm (perinuclear region), isoform 4: nucleus, membrane, cytoplasm | Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, TGFBR1-TGFBR2 complex | Cell survival, circadian rhythm, cell metabolism, inflammatory response, antiviral response, metastasis, cell growth, cell cycle (G0-G1), HR-mediated DNA repair | ML364 | Davis et al[26] and Luo et al[76] |
USP2a | Oncogene | Cyclin D1 | Cell cycle progression, development | LCAHA | Magiera et al[23] | ||
4 | USP3 | Tumor suppressor | Nucleus | SMAD4 | TGF-β pathway, CRC migration, metastasis, invasion | miR-224 | Das et al[33], Wang et al[71], and Zheng et al[87] |
Oncogene | Androgen receptor, RASGRP3, Cdc25A | MAPK pathway, apoptosis, cell cycle progression, CRC non-invasive biomarker | AC092894.1 | ||||
5 | USP4 | Oncogene | Cytoplasm, nucleus | PRL-3, β-catenin, Rheb | AKT, EMT, E-Cadherin, Wnt/β-catenin pathway, colony formation, mTORC1 activation, tumorigenesis, progression | Vialinin A, PR619, NR (neutral red) | Yun et al[56], Xing et al[65], Nguyen et al[90], Deng et al[97], Wang et al[98], and Zhao et al[99] |
6 | USP5 | Tumor suppressor | Cytosol, lysosome, nucleus | ORP8 | ER stress, apoptosis, progression/drug resistance | G9, vialinin A, WP1130, EOAI3402143, AM146, RA-9, RA-14, PR619, doxorubicin | Xu et al[81], Zhang et al[100], and Ning et al[101] |
Oncogene | TUFM | Cell growth | |||||
7 | USP6 | Oncogene | Cell membrane, cytoplasm, endosome | Deubiquitination, development, progression | Zeng et al[72] | ||
8 | USP6NL | Oncogene | Golgi apparatus, cytoplasmic vesicle | β-catenin (P27, c-MYC, CyclinD1) | Wnt/β-catenin pathway, proliferation, metastasis, progression | Sun et al[64] | |
9 | USP7 (HAUSP) | Tumor suppressor | Nucleus, cytoplasm, nucleus (PML body), chromosome | MDM2, p53 | Tumor growth, development, progression, drug resistance | IL-6/STAT3/HDAC-1, P22077, HBX41, P0045204, P005091, N-benzylpiperidinol, HBX19,FT671, GNE6640, GNE6776, C7, C19, parthenolide | Choi et al[36], Novellasdemunt et al[58], Novellasdemunt et al[59], Sarkar[60], Basu et al[61], Hou et al[62], Zhou et al[80], An et al[91], Weinstock et al[92], Li et al[93], Nicholson et al[102], Colland et al[103], Qian et al[104], Bufalieri et al[105], Li et al[106], Becker et al[107], Yang et al[108], Du et al[109], Zhu et al[110] |
Oncogene | DNMT1, β-catenin, FAM188B, DDX3X, c-MYC, P53, HDM2, DNA damage repair proteins DNA polymerase eta (Polη), PCNA | Tumor growth, WNT/β-catenin pathway, apoptosis, cell growth, stress-tolerance pathway, tumorigenesis, proliferation | |||||
10 | USP9X | Tumor suppressor | Cytosol, cell projection (growth cone), cytoplasm (cytoskeleton, cilium axoneme) | FBW7 | C-MYC, C-JUN, cyclin E, development, progression, drug resistance (5-FU) | G9, WP1130, PR619 | Harris et al[27], Peddaboina et al[40], and Tian et al[111] |
Oncogene | BCL-XL, MCL-1 | Apoptosis | |||||
11 | USP10 | Tumor suppressor | Cytoplasm, nucleus, early endosome | SIRT6, P53 | c-MYC, progression | P22077, HBX19818, spautin-1, PR619 | Lin et al[28], Kim et al[29], Li et al[34], Reissland et al[51], Li et al[78], Ouyang et al[112], and Ye et al[113] |
Oncogene | NLRP7, MSI2, miR-1286, β-catenin | Tumor promotion, NF-kB pathway, cancer proliferation, invasion, metastasis, WNT/β-catenin pathway | |||||
12 | USP11 | Tumor suppressor | Nucleus, cytoplasm, chromosome | P21 | Apoptosis | miR-132-3P | Zhang et al[42], Sun et al[66], Liao et al[67], Tian et al[111], Lee et al[114], Huang et al[115], and Sun et al[116] |
Oncogene | PPP1CA, IGF2BP3, Cyclin D1, c-IAP2, VCP | Tumor growth, metastasis, apoptosis, ERK/MAPK pathway, autophagy AMPK/Akt/mTOR pathway, proliferation, migration, development, progression, drug resistance (5-FU) | |||||
13 | USP13 | Tumor suppressor | Cytosol, nucleoplasm, nucleus | PTEN | Cell proliferation, glycolysis, development | miR-135b | Xiang et al[117] |
14 | USP14 | Oncogene | Cytoplasm, cell membrane | JNK, β-catenin, Dvl, NLRC5, RIG-I, FASN, CXCR4 | MAPK/JNK signaling, immune regulation, tumorigenesis, proliferation, Wnt/β-catenin pathway, liver/lymph node metastases, progression, drug resistance (IDO1), correlated with pathological stage | b-AP15 | Sarkar[60], Liu et al[118], Mofers et al[119], Du et al[120], and Shi et al[121] |
15 | USP15 | Tumor suppressor | Cytoplasm, nucleus, mitochondrion | APC | Wnt/β-catenin pathway, development | Huang et al[122] | |
16 | USP17 | Tumor suppressor | Nucleus, endoplasmic reticulum | DNA damage response, chemosensitization | ZEB1 | Wang et al[123] | |
17 | USP18 | Oncogene | Cytoplasm, nucleus | SNAIL | EMT, development, progression, drug resistance | Huang et al[68], and Zhang et al[124] | |
18 | USP19 | Oncogene | Endoplasmic reticulum membrane | ME1 | Lipogenesis, NADPH production, inhibiting ROS, tumorigenesis, carcinogenesis, development | Zhu et al[125] | |
19 | USP20 | Oncogene | Cytoplasm, endoplasmic reticulum, cytoplasm (perinuclear region), cytoplasm (centrosome) | SOX4, ADORA2A, CD160, CD27, TNFRSF25, MRP1, MRP3, MRP5 | E-Cadherin, N-Cadherin, SNAIL, Slug, migration, Invasion, Metastasis, Notch/Hedgehog/β-catenin pathway, progression, drug Resistance | PR619 | Guan et al[53], Jin et al[79], and Ming et al[86] |
20 | USP21 | Oncogene | Cytoplasm, nucleus | Fra-1, RIG-I, NANOG, Foxp3 | Metastasis, apoptosis, DNA repair, MMP1, tumor development/growth, NF-κB pathways, progression | Gallic Acid, BAY-805 | Kang et al[52], Yun et al[73], Deng et al[94], and Göricke et al[95] |
21 | USP22 | Tumor suppressor | Nucleus | SIRT1, SPARC(H2B) | STAT3-MMP9 pathway, mTOR, inflammation-associated CRC | PR619, miR-30a-5p | Lin et al[25], Jiang et al[48], Yan et al[49], Miao et al[50], Li et al[54], Guo et al[96], Liu et al[126], Jiang et al[127], Xu et al[128], Ao et al[129], Ao et al[130], Kosinsky et al[131], Liu et al[132], Sippl et al[133], Liu et al[134], Kapoor[135], Liu et al[136], Wang et al[137], Gennaro et al[138], Kosinsky et al[139], He et al[140], Feng et al[141], Kosinsky et al[142], Xian et al[143], and Kotelevets et al[144] |
Oncogene | AP-4, BMI-1, PD-L1, β-catenin, ZRANB1, Sox9, FOXP3, Akt, INK4a, ARF, CCND1, SNHG16, Axin2 miR-132-3p, MVP, cyclinD2 c-MYC, Pakt, CCND1(CyclinD1), H2B(RNF2), HSP90, AB1 | Cell transition (G1-S)/(G2-M), EMT, Wnt/β-catenin pathway, RNF-22, proliferation, invasion, stemness, INK4a/ARF pathway, AKT signaling, apoptosis, immune escape, tumorigenesis, lymph node metastasis, development, progression, drug resistance (5-FU, Ganetespib), therapy resistant phenotype | |||||
22 | USP25 | Oncogene | Cytoplasm, nucleus | STAT3, SOCS3, EGFR | WNT pathway, EGF pathway, tumorigenesis, development | Vismodegib | Wang et al[30] and Wang et al[55] |
23 | USP28 | Oncogene | Nucleus (nucleoplasm) | FBW7α, FOX1, NICD1, FOXC1, FBP1, Checkpoint | c-MYC, c-JUN, aerobic glycolysis, notch signaling, proliferation, tumorigenesis, progression | Vismodegib, FT206 | Wang et al[30], Diefenbacher et al[31], Bernhard et al[32], Zhou et al[89], Popov et al[145], Liu et al[146], Xu et al[147], and Ren et al[148] |
24 | USP29 | Oncogene | Cytoplasm (perinuclear region) | KIAA1429, SOX8 | Proliferation, DNA damage, apoptosis, migration, invasion, progression | Chandrasekaran et al[149] and Li et al[150] | |
25 | USP33 | Tumor suppressor | Cytoplasm (perinuclear region), cytoplasm (centrosome), Golgi apparatus | ROBO1 | SLIT2 pathway, progression | Huang et al[74] | |
26 | USP34 | Oncogene | Cytosol, nucleus | AXIN1, AXIN2 | WNT pathway, development | Lui et al[151] | |
27 | USP35 | Oncogene | Cytosol, nucleus | FUCA1, NER | Proliferation, drug resistance (5-FU/OXA) | Xiao et al[85] | |
28 | USP38 | Tumor suppressor | Cytosol, nucleus | HDAC3, HMX3 | Stemness markers, apoptosis, KRAS pathways, proliferation, migration, invasion, development, progression, drug resistance | Zhan et al[45], Wang et al[77], and Liu et al[82] | |
Oncogene | LSD1 | Proliferation, cell colony formation | |||||
29 | USP39 | Oncogene | Nucleus | β-catenin, TCF-4, MMP2, MMP9, KRAS, P21, CHK2, TCF/LEF, Aurora B | Wnt/β-catenin pathway, cell Cycle progression, c-MYC, cell Growth, cyclin D1, PPARd, invasion, tumorigenesis, proliferation, apoptosis, angiogenesis, spindle checkpoint and cytokinesis, colony formation, development | Yuan et al[41], Yuan et al[63], Fraile et al[152], Remitha et al[153] | |
30 | USP42 | Tumor suppressor | Cytosol, nucleoplasm, nucleus | RNF43, ZNRF3 | WNT pathway | Giebel et al[57] | |
Mesenchymal genes, Endothelial Genes | EMT, development, progression | ||||||
31 | USP43 | Oncogene | Nucleoplasm | ZEB1 | EMT pathway, proliferation, migration, invasion, progression | Ye et al[154] | |
32 | USP44 | Tumor suppressor | Chromatin, cytoplasm, mitotic spindle, nucleoplasm, nucleus | PCNA, cleaved-caspase3, Axin 1 | Apoptosis, colorectal neoplasia, Wnt/β-catenin pathway, development, progression | Huang et al[38], Lou et al[39], and Sloane et al[155] | |
33 | USP46 | Tumor suppressor | Cytosol, nucleus | PHLPP | AKT pathway, development, progression hypoxia-induced drug resistance | Wen et al[83], and Li et al[156] | |
34 | USP47 | Oncogene | Cytoplasm | SNAIL, LINC00668, β-catenin, SATB1, SMURF2, YAP, RP52 | EMT, stemness, tumor growth, chromatin remodeling, proliferation, migration, invasion, hippo Pathway, RP52-MDM2 interaction, colony formation, development, progression | Parthenolide, P5091, Cpd14, P22077, PR619 | Cho et al[37], Zhang et al[46], Yu et al[47], Yan et al[75], Choi et al[157], Yu et al[158], Pan et al[159], and Pan et al[160] |
35 | USP49 | Tumor suppressor | nucleus | miR-5000-3P | PI3K/AKT pathway, proliferation, migration, progression, drug sensitivity (oxaliplatin) | Tu et al[43], and Zhuang et al[84] | |
Oncogene | BAG2 | Apoptosis | |||||
36 | USP54 | Oncogene | Mitochondria | Proliferation, migration, invasion, tumorigenesis, development, progression | Fraile et al[161] |
- Citation: Al-Balushi E, Al Marzouqi A, Tavoosi S, Baghsheikhi AH, Sadri A, Aliabadi LS, Salarabedi MM, Rahman SA, Al-Yateem N, Jarrahi AM, Halimi A, Ahmadvand M, Abdel-Rahman WM. Comprehensive analysis of the role of ubiquitin-specific peptidases in colorectal cancer: A systematic review. World J Gastrointest Oncol 2024; 16(1): 197-213
- URL: https://www.wjgnet.com/1948-5204/full/v16/i1/197.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i1.197